


IN THE CLAIMS

Claims 1-47 (canceled)

48. (New) A compound of Formula:



or a pharmaceutically acceptable salt, solvate or a prodrug thereof,
wherein:

R¹ is alkyl; and

R⁴ is: hydrogen; halo; alkyl; alkoxy; hydroxy; or cycloalkylalkyloxy.

49. (New) The compound of claim 48, wherein R¹ is methyl or ethyl.

50. (New) The compound of claim 48, wherein R⁴ is: hydrogen; methyl; fluoro; chloro; methoxy; ethoxy; or cyclopropylmethoxy.

51. (New) The compound of claim 48, wherein R⁴ is chloro.

52. (New) The compound of claim 48, wherein said compound is selected from:

N-[4-(4,5-Dihydro-1*H*-imidazol-2-ylmethyl)-phenyl]-methanesulfonamide;

N-[4-(4,5-Dihydro-1*H*-imidazol-2-ylmethyl)-2-methoxy-phenyl]-methanesulfonamide;

N-[4-(4,5-Dihydro-1*H*-imidazol-2-ylmethyl)-2-methyl-phenyl]-methanesulfonamide;

N-[2-Chloro-4-(4,5-dihydro-1*H*-imidazol-2-ylmethyl)-phenyl]-methanesulfonamide;

N-[4-(4,5-Dihydro-1*H*-imidazol-2-ylmethyl)-2-hydroxy-phenyl]-methanesulfonamide;

Ethanesulfonic acid [2-chloro-4-(4,5-dihydro-1*H*-imidazol-2-ylmethyl)-phenyl]-amide;

Propane-2-sulfonic acid [2-chloro-4-(4,5-dihydro-1*H*-imidazol-2-ylmethyl)-phenyl]-amide;


N-[2-Ethoxy-4-(4,5-dihydro-1*H*-imidazol-2-ylmethyl)-phenyl]-methanesulfonamide;

Ethanesulfonic acid [4-(4,5-dihydro-1*H*-imidazol-2-ylmethyl)-2-methoxy-phenyl]-amide;

N-[2-Bromo-4-(4,5-dihydro-1*H*-imidazol-2-ylmethyl)-phenyl]-methanesulfonamide; and

N-[4-(4,5-Dihydro-1*H*-imidazol-2-ylmethyl)-2-fluoro-phenyl]-methanesulfonamide.

53. A method for producing the compound of claim 48, said method comprising contacting a nitrile compound of the formula:



wherein R¹³ is alkyl and R¹ and R⁴ are as recited in claim 1;

with ethylene diamine,

to produce the compound of claim 1.

54. A composition comprising:

- (a) a therapeutically effective amount of a compound of Claim 48; and
- (b) a pharmaceutically acceptable carrier.

55. A method for treating a disease state selected from the groups consisting of urge incontinence, stress incontinence, overflow incontinence, functional incontinence, sexual dysfunction, nasal congestion, and CNS disorders selected from the group depression,

anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and cognition, eating disorders, obesity, bulimia and anorexia, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of Claim 48.

56. A method for treating a disease state comprising urinary incontinence by administering to a subject in need of such treatment an effective amount of a Compound of Claim 48.

57. The method of Claim 56, wherein the disorder is stress incontinence.

58. The method of Claim 56, wherein the disorder is urge incontinence.

59. A method for treating nasal disorder by administering to a mammal in need of such treatment an effective amount of a Compound of Claim 48.

60. The method of Claim 59, wherein the nasal disorder is nasal congestion.

61. The method of Claim 59, wherein the nasal congestion is sinusitis or otitis.

62. A method for treating sexual dysfunction by administering to a mammal in need of such treatment an effective amount of a Compound of Claim 48.